Companies › Idorsia Pharmaceuticals
3 active drug programs in 8 registered trials: 3 Phase 3, 3 Phase 2, 2 Phase 4; Neurology, Psychiatry, Immunology, Metabolic and endocrine; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Daridorexant Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR2, HCRTR1 | Phase 3 | Insomia Disorder; Learning; Alzheimer Disease; Postoperative Cognitive Decline … | Nov 2027 |
| Lucerastat Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Fabry Disease | Feb 2029 |
| ACT-777991 | – | Phase 2 | Non-Segmental Vitiligo | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03737214 | Lucerastat | Phase 3 | Fabry Disease | Metabolic and endocrine | Aug 2026 |
| NCT07267559 | Daridorexant | Phase 4 | Learning | Psychiatry | Sep 2026 |
| NCT05924425 | Daridorexant | Phase 4 | Alzheimer Disease | Neurology | May 2027 |
| NCT07667569 | ACT-777991 | Phase 2 | Non-Segmental Vitiligo | Immunology | Jun 2027 |
| NCT07217912 | Daridorexant | Phase 2 | Postoperative Cognitive Decline | Neurology | Nov 2027 |
| NCT07843329 | Daridorexant | Phase 3 | Insomia Disorder | Neurology | Nov 2027 |
| NCT07213349 | Daridorexant | Phase 2 | Alzheimer Disease (AD) | Neurology | Dec 2028 |
| NCT07778667 | Lucerastat | Phase 3 | Fabry Disease | Metabolic and endocrine | Feb 2029 |
Merck & Co. (MSD) Johnson & Johnson (Janssen) Amicus Therapeutics Sanofi Azafaros
Upsher-Smith Laboratories ACADIA Pharmaceuticals Pharming Technologies PTC Therapeutics Sichuan Jishengtang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.